Headline News

A phase 2 clinical trial of dalzanemdor in those with cognitive impairment associated with Huntington’s disease failed to meet its primary and secondary endpoints, causing the manufacturer to halt development of the investigational therapy.

Roflumilast foam 0.3% improved patient-reported outcomes in scalp and body psoriasis, according to a poster presentation at the Fall Clinical Dermatology Conference.

Results from the OASIS 4 trial revealed that people with overweight or obesity assigned to once-daily oral semaglutide had a higher likelihood of significant weight loss compared with those receiving placebo plus lifestyle intervention.

In this episode, guest Cammie Wolf Rice discusses the opioid crisis, how it impacted her life and family and her foundation’s mission to combating the epidemic and spreading awareness.

Results presented at the Orthopaedic Trauma Association Annual Meeting showed short proximal femoral nails may toggle secondary to a proximal fixation defect if used for intertrochanteric fractures in patients with wide medullary canals.

BOSTON — Targeting asthma remission as the next goal in asthma therapy should be prioritized, according to a presentation at the CHEST Annual Meeting.

In this Healio video exclusive, Joanne Stone, MD, MS, and Susan S. Khalil, MD, discussed highlights from the second annual Mount Sinai Women’s Health Forum, a 1-day conference dedicated to the latest updates in care for midlife women.

CHICAGO — In this video, Karl G. Csaky, MD, PhD, discusses highlights from the AAO annual meeting.

Unintended pregnancy after kidney transplantation was not linked to perinatal acute allograft rejection but was associated with mycophenolate exposure and allograft loss at 2 years postpartum, according to data published in O&G Open.

CHICAGO — A potassium binder helped patients with HF who have or are at high risk for hyperkalemia stay on spironolactone at an optimal dose, but showed a signal of HF hospitalization risk, researchers reported.